Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ADTX
ADTX | US
3.47
USD3.00
645.27%
ADTX | US
Loading StockChartView...
About ADTX
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
3.47
Open
4.10
High
4.37
Low
2.92
Aditxt Inc. a biotech company develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand manage and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation including skin grafting autoimmune diseases and allergies. Aditxt Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics Inc. and changed its name to Aditxt Inc. in July 2021. Aditxt Inc. was incorporated in 2017 and is headquartered in Richmond Virginia.
View LessADTX | US
Risk
2297.6
Sharpe
-0.16
Luna's Score
36/100
Recommendation
Sell
Luna says (ADTX | US)
What's Working
Strength based on increasing price with high volume
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
3092.9%1 month
2297.6%3 months
1317.4%6 months
936.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
0.37
Price to book
0.69
Debt to equity
1.22
Debt to assets
0.28
Ent. to EBITDA
0.02
Ent. to rev.
37.49
PEG
-
Other Fundamentals
EBITDA
-33.09M
MarketCap
14.65M
MarketCap(USD)
14.65M
Div. yield
-
Op. margin
-13.50K
Erngs. growth
-
Rev. growth
-80.00
Ret. on equity
-3.49K
Short ratio
0.09
Short perc.
4.27
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.95
Range1M
3.95
Range3M
3.95
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.59
Price X volume
925.80K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.02 | 0.53 | Cheaper |
| Ent. to Revenue | 37.49 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.69 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 1,317.43 | 72.80 | Riskier |
| Debt to Equity | 1.22 | -1.23 | Expensive |
| Debt to Assets | 0.28 | 0.25 | Par |
| Market Cap | 14.65M | 3.66B | Emerging |
